How This Company Targets the Medical Device Market

How This Company Targets the Medical Device Market

Alere strengthened its standing in the mobile health market last year by acquiring MedApps. It kept the team intact and renamed it Alere Connect. Now Alere Connect, with less than 30 employees, is ramping up from 2,000 monitoring devices this year to more than 10,000 in 2014.

Motley Fool analysts Max Macaluso and Rex Moore were able to speak with Alere Connect CEO Kent Dicks at the recent mHealth Summit near Washington, D.C. When designing new products, does his company look at a particular therapeutic area first, or develop the technology first and then try to apply it to certain problems? In this segment of a four-part interview, Dicks explains that you must know your market before developing a device, and that he targets the 15% of the market that consumes 80% of health-care costs.

Investing smartly
One of the dirty secrets that few finance professionals will openly admit is the fact that dividend stocks as a group handily outperform their non-dividend paying brethren. The reasons for this are too numerous to list here, but you can rest assured that it's true. However, knowing this is only half the battle. The other half is identifying which dividend stocks in particular are the best. With this in mind, our top analysts put together a free list of nine high-yielding stocks that should be in every income investor's portfolio. To learn the identity of these stocks instantly and for free, all you have to do is click here now.

The article How This Company Targets the Medical Device Market originally appeared on

Max Macaluso, Ph.D. and Rex Moore have no position in any stocks mentioned, and neither does The Motley Fool. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Originally published